Cancer and COVID-19: Why Are Cancer Patients More Susceptible to COVID-19?

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2021 Jul 24

PMID 34302557

Citations 27

Authors

Saptarshi Sinha

Chanakya Nath Kundu

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic has engulfed the entire world and has claimed more than 3 million lives worldwide. This viral disease is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and mainly characterized by fever, dry cough, fatigue, anosmia, anorexia, and dyspnea. The severity of the disease increases with age and presence of comorbidities, including cancer. Multiple clinical studies have shown that the cancer patients are highly susceptible to the severe form of the viral disease. In this review article, we have summarized the available scientific literature regarding the molecular links between COVID-19 and cancer, which make the cancer patients highly susceptible to COVID-19. Few studies have shown that the angiotensin-converting enzyme 2 (ACE2) receptor, transmembrane protease serine 2 (TMPRSS2), and the immune response and inflammation establish the interconnection between the two diseases. Additionally, we have also discussed whether SARS-CoV-2 can contribute to cancer development in COVID-19 patients. A recent study has suggested that SARS-CoV-2 may create a microenvironment that may support cancer cell proliferation and induce the activation of dormant cancer cells (DCCs). In another study, the blood sera of COVID-19 patients were found to activate epithelial-to-mesenchymal transition (EMT) in cancer cells. Overall, this review article will surely help the scientific community to understand why the cancer patients are so much prone to COVID-19 and will also motivate the researchers to find new therapeutic strategies that may save the lives of many COVID-19-infected cancer patients.

Citing Articles

Reactive oxygen species induced by SARS-CoV-2 infection can induce EMT in solid tumors: Potential role of COVID-19 in chemo-resistance and metastasis.

Moulaeian M, Ferdousmakan S, Banihashemi S, Homayounfar S, Pasupulla A, Malekzadegan Y Heliyon. 2024; 10(22):e40297.

PMID: 39624316 PMC: 11609686. DOI: 10.1016/j.heliyon.2024.e40297.

The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19.

Niayesh-Mehr R, Kalantar M, Bontempi G, Montaldo C, Ebrahimi S, Allameh A Cell Commun Signal. 2024; 22(1):542.

PMID: 39538298 PMC: 11558984. DOI: 10.1186/s12964-024-01925-y.

Unusual Presentation of Metastatic Medullary Thyroid Cancer Involving Bone Marrow, Kidneys, and Adrenal Gland: A Literature Review Based on a Case Report.

Ebrahimi P, Payab M, Shariati A, Alipour N, Nozheh A, Tavangar S Cancer Rep (Hoboken). 2024; 7(10):e70022.

PMID: 39410877 PMC: 11480645. DOI: 10.1002/cnr2.70022.

Oncogenic potential of SARS-CoV-2-targeting hallmarks of cancer pathways.

Jaiswal A, Shrivastav S, Kushwaha H, Chaturvedi R, Singh R Cell Commun Signal. 2024; 22(1):447.

PMID: 39327555 PMC: 11426004. DOI: 10.1186/s12964-024-01818-0.

Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition.

Pi P, Zeng Z, Zeng L, Han B, Bai X, Xu S Front Pharmacol. 2023; 14:1218059.

PMID: 37601070 PMC: 10436482. DOI: 10.3389/fphar.2023.1218059.

References

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R . Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31(7):894-901. PMC: 7270947. DOI: 10.1016/j.annonc.2020.03.296. View

Saini K, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G . Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 2020; 7(6):e432-e435. PMC: 7195053. DOI: 10.1016/S2352-3026(20)30123-X. View

Venkataraman T, Coleman C, Frieman M . Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection. J Virol. 2017; 91(12). PMC: 5446658. DOI: 10.1128/JVI.00182-17. View

Moore J, June C . Cytokine release syndrome in severe COVID-19. Science. 2020; 368(6490):473-474. DOI: 10.1126/science.abb8925. View

Bhardwaj K, Liu P, Leibowitz J, Kao C . The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. J Virol. 2012; 86(8):4294-304. PMC: 3318636. DOI: 10.1128/JVI.07012-11. View

Yu J, Ouyang W, Chua M, Xie C . SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020; 6(7):1108-1110. PMC: 7097836. DOI: 10.1001/jamaoncol.2020.0980. View

McGonagle D, ODonnell J, Sharif K, Emery P, Bridgewood C . Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020; 2(7):e437-e445. PMC: 7252093. DOI: 10.1016/S2665-9913(20)30121-1. View

Sidaway P . COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol. 2020; 17(6):336. PMC: 7136993. DOI: 10.1038/s41571-020-0366-2. View

Merad M, Martin J . Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020; 20(6):355-362. PMC: 7201395. DOI: 10.1038/s41577-020-0331-4. View

10.

Hindson J . COVID-19: faecal-oral transmission?. Nat Rev Gastroenterol Hepatol. 2020; 17(5):259. PMC: 7095230. DOI: 10.1038/s41575-020-0295-7. View

11.

Sica A, Colombo M, Trama A, Horn L, Garassino M, Torri V . Immunometabolic Status of COVID-19 Cancer Patients. Physiol Rev. 2020; 100(4):1839-1850. PMC: 7839651. DOI: 10.1152/physrev.00018.2020. View

12.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K . Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3):335-337. PMC: 7159000. DOI: 10.1016/S1470-2045(20)30096-6. View

13.

Jose R, Manuel A . COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020; 8(6):e46-e47. PMC: 7185942. DOI: 10.1016/S2213-2600(20)30216-2. View

14.

Spicer J, Chamberlain C, Papa S . Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol. 2020; 17(6):329-331. PMC: 7156894. DOI: 10.1038/s41571-020-0370-6. View

15.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

16.

Tay M, Poh C, Renia L, Macary P, Ng L . The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6):363-374. PMC: 7187672. DOI: 10.1038/s41577-020-0311-8. View

17.

Sungnak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M . SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020; 26(5):681-687. PMC: 8637938. DOI: 10.1038/s41591-020-0868-6. View

18.

Bhattacharjee A, Patil V, Dikshit R, Prabhash K, Singh A, Chaturvedi P . Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic. Head Neck. 2020; 42(6):1173-1178. PMC: 7264597. DOI: 10.1002/hed.26196. View

19.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

20.

Hoffmann M, Kleine-Weber H, Pohlmann S . A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020; 78(4):779-784.e5. PMC: 7194065. DOI: 10.1016/j.molcel.2020.04.022. View